The Effects of Zoledronic Acid on Bone Architecture in Premenopausal Women with Breast Cancer Receiving Adjuvant Combined Ovarian Suppression and Aromatase Inhibitor Therapy: A Randomised Controlled Trial.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1114804

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

In premenopausal women, a new treatment method that reduces oestrogen levels to almost zero significantly reduces the risk of breast cancer recurrence. However, this is likely to cause substantial bone loss leading to fractures. Using a new imaging technique (HR-pQCT), the effects of profound oestrogen deprivation on bone structure in premenopausal women will be studied. The ability of zoledronic acid, a drug that reduces bone loss, to prevent these adverse bone effects will also be examined.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2019

Funding Scheme: Postgraduate Scholarships

Funding Amount: $122,714.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Endocrinology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

bone architecture | bone remodelling | breast cancer | hormone therapy | premenopausal women

Related Links